This Article Full Text Full Text (PDF) Supplementary Data Tables Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsu, D. S. Articles by Potti, A. Search for Related Content PubMed PubMed Citation Articles by Hsu, D. S. Articles by Potti, A. Related Articles Related Editorial Social Bookmarking                            What's this?

Pharmacogenomic Strategies Provide a Rational Approach to the Treatment of Cisplatin-Resistant Patients With Advanced Cancer

David S. Hsu, Bala S. Balakumaran, Chaitanya R. Acharya, Vanja Vlahovic, Kelli S. Walters, Katherine Garman, Carey Anders, Richard F. Riedel, Johnathan Lancaster, David Harpole, Holly K. Dressman, Joseph R. Nevins, Phillip G. Febbo, Anil Potti

From the Division of Medical Oncology, Department of Medicine; Institute for Genome Sciences and Policy; Department of Surgery, Duke University, Durham, NC; and the Division of Gynecologic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL

Address reprint requests to Anil Potti, MD, Duke University, Department of Medicine, Box 3841 Medical Center, Durham, NC 27710; e-mail: anil.potti{at}duke.edu

Purpose Standard treatment for advanced non–small-cell lung cancer (NSCLC) includes the use of a platinum-based chemotherapy regimen. However, response rates are highly variable. Newer agents, such as pemetrexed, have shown significant activity as second-line therapy and are currently being evaluated in the front-line setting. We utilized a genomic strategy to develop signatures predictive of chemotherapeutic response to both cisplatin and pemetrexed to provide a rational approach to effective individualized medicine.

Methods Using in vitro drug sensitivity data, coupled with microarray data, we developed gene expression signatures predicting sensitivity to cisplatin and pemetrexed. Signatures were validated with response data from 32 independent ovarian and lung cancer cell lines as well as 59 samples from patients previously treated with cisplatin.

Results Genomic-derived signatures of cisplatin and pemetrexed sensitivity were shown to accurately predict sensitivity in vitro and, in the case of cisplatin, to predict treatment response in patients treated with cisplatin. The accuracy of the cisplatin predictor, based on available clinical data, was 83.1% (sensitivity, 100%; specificity 57%; positive predictive value, 78%; negative predictive value, 100%). Interestingly, an inverse correlation was seen between in vitro cisplatin and pemetrexed sensitivity, and importantly, between the likelihood of cisplatin and pemetrexed response in patients.

Conclusion The use of genomic predictors of response to cisplatin and pemetrexed can be incorporated into strategies to optimize therapy for advanced solid tumors.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Tumor mRNA Expression Profiles Predict Responses to Chemotherapy
  John D. Minna, Luc Girard, and Yang Xie
  JCO 2007 25: 4329-4336 [Full Text]

This article has been cited by other articles:

				A. Anguiano, S. A. Tuchman, C. Acharya, K. Salter, C. Gasparetto, F. Zhan, M. Dhodapkar, J. Nevins, B. Barlogie, J. D. Shaughnessy Jr, et al. Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma J. Clin. Oncol., September 1, 2009; 27(25): 4197 - 4203. [Abstract] [Full Text] [PDF]

				D. S. Hsu, C. R. Acharya, B. S. Balakumaran, R. F. Riedel, M. K. Kim, M. Stevenson, S. Tuchman, S. Mukherjee, W. Barry, H. K. Dressman, et al. Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer PNAS, March 31, 2009; 106(13): 5312 - 5317. [Abstract] [Full Text] [PDF]

				R. N. Bose, L. Maurmann, R. J. Mishur, L. Yasui, S. Gupta, W. S. Grayburn, H. Hofstetter, and T. Salley Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells PNAS, November 25, 2008; 105(47): 18314 - 18319. [Abstract] [Full Text] [PDF]

				R. F. Riedel, A. Porrello, E. Pontzer, E. J. Chenette, D. S. Hsu, B. Balakumaran, A. Potti, J. Nevins, and P. G. Febbo A genomic approach to identify molecular pathways associated with chemotherapy resistance Mol. Cancer Ther., October 1, 2008; 7(10): 3141 - 3149. [Abstract] [Full Text] [PDF]

				L. H. Einhorn First-Line Chemotherapy for Non-Small-Cell Lung Cancer: Is There a Superior Regimen Based on Histology? J. Clin. Oncol., July 20, 2008; 26(21): 3485 - 3486. [Full Text] [PDF]

				B. Singh and D. G. Pfister Individualized Treatment Selection in Patients With Head and Neck Cancer: Do Molecular Markers Meet the Challenge? J. Clin. Oncol., July 1, 2008; 26(19): 3114 - 3116. [Full Text] [PDF]

				J.-C. Ko, S.-C. Ciou, C.-M. Cheng, L.-H. Wang, J.-H. Hong, M.-Y. Jheng, S.-T. Ling, and Y.-W. Lin Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells Carcinogenesis, July 1, 2008; 29(7): 1448 - 1458. [Abstract] [Full Text] [PDF]

				T. A. D'Amico Molecular Biologic Staging of Lung Cancer Ann. Thorac. Surg., February 1, 2008; 85(2): S737 - S742. [Abstract] [Full Text] [PDF]

				J. D. Minna, L. Girard, and Y. Xie Tumor mRNA Expression Profiles Predict Responses to Chemotherapy J. Clin. Oncol., October 1, 2007; 25(28): 4329 - 4336. [Full Text] [PDF]